nanobiotix

Nanomedicine company Nanobiotix elects former Sanofi-Aventis oncology researcher Elsa Borghi, MD, as its medical director

Nanobiotix, an emerging nanomedicine company focused on cancer therapy, announced today that it has appointed Elsa Borghi,MD, as medical director. Previously, Dr.Borghi worked in the RD oncology department for Sanofi-Aventis,one of the five largest pharmaceutical companies in the world, until the onset of 2008, when she joined Nanobiotix. She has led successful clinical trials worldwide for major drugs and registration in the Oncology field. Dr. Borghi began working in the pharmaceutical industry in 1996 on drug safety and international reporting, mainly for oncology and cardiovascular drugs. She began working on pivotal cancer clinical trials in 1999, including early colon cancer, early- and late-stage breast cancer, and prostate cancer, for which she was responsible for a chemotherapy product registration. In addition, Dr.Borghi has worked on soft tissue sarcoma, lung cancer and phase I studies for chemotherapies, antisense and targeted therapies. Most of her recent work was focused on tumor perfusion modifiers such as antivascular agents. Dr. Borghi obtained her medical degree from the University of Cordoba School of Medicine in March 1984 and the French equivalent in 1994 from the University of Paris V.

“The appointment of such an experienced clinical manager and scientific researcher as Dr. Borghi is a very significant milestone for Nanobiotix,” said Laurent Levy, Ph.D., chief executive officer of Nanobiotix. “With strong preclinical work behind us, we are looking forward to the next giant step for Nanobiotix, our first-in-man and the start of clinical trials in the not-too-distant future. We therefore expect to benefit from Dr. Borghi’s substantial accomplishments related to turning promising research into approved products designed to produce favorable outcomes for patients.”